Equity Overview
Price & Market Data
Price: $20.00
Daily Change: +$10.64 / 53.20%
Daily Range: $20.00 - $20.00
Market Cap: $415,884,161
Daily Volume: 101
Performance Metrics
1 Week: 113.7%
1 Month: 113.7%
3 Months: 113.7%
6 Months: 113.7%
1 Year: 113.7%
YTD: %
Details
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.